Synthesis of a new hapten for generating catalytic antibodies that activate doxorubicin prodrugs

In order to assess a novel strategy for catalytic activation of a new prodrug of doxorubicin, a new hapten has been designed and prepared, which can be used to induce an immune response from which catalytic antibodies (cAbs) may be produced.